Cargando…
Omacetaxine mepesuccinate induces apoptosis and cell cycle arrest, promotes cell differentiation, and reduces telomerase activity in diffuse large B-cell lymphoma cells
Clinical studies have demonstrated that omacetaxine mepesuccinate exerts beneficial effects on acute myelogenous leukemia. It has been suggested that omacetaxine mepesuccinate, used alone or with interferon-α or cytarabine, induces remission in patients with chronic myelogenous leukemia. These effec...
Autores principales: | ZHANG, LINA, CHEN, ZHENZHU, ZUO, WENLI, ZHU, XINGHU, LI, YUFU, LIU, XINJIAN, WEI, XUDONG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805079/ https://www.ncbi.nlm.nih.gov/pubmed/26935769 http://dx.doi.org/10.3892/mmr.2016.4899 |
Ejemplares similares
-
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
por: Chen, Yaoyu, et al.
Publicado: (2014) -
Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines
por: Kulkarni, Hemant, et al.
Publicado: (2012) -
Omacetaxine Mepesuccinate: A New Treatment Option for Patients With Chronic Myelogenous Leukemia
por: Kurtin, Sandra E., et al.
Publicado: (2013) -
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
por: Nemunaitis, John, et al.
Publicado: (2012) -
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
por: Akard, Luke, et al.
Publicado: (2015)